Cerus Corporation

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.
Company Growth (employees)
Type
Public
HQ
Concord, US
Size (employees)
204 (est)+16%
Website
cerus.com
Cerus Corporation is headquartered in Concord, US

Key People at Cerus Corporation

William M. Greenman

William M. Greenman

President and CEO
Kevin D. Green

Kevin D. Green

VP, Finance & CFO
Laurence M. Corash

Laurence M. Corash

SVP, CMO & CSO

Cerus Corporation Office Locations

Cerus Corporation has offices in Concord and Amersfoort
Concord, US (HQ)
2550 Stanwell Dr
Amersfoort, NL
79 Stationsstraat

Cerus Corporation Data and Metrics

Cerus Corporation Financial Metrics

Cerus Corporation's revenue was reported to be $39.3 m in FY, 2016
USD

Net income (Q1, 2017)

(18.6 m)

EBIT (Q1, 2017)

(18.1 m)

Market capitalization (25-Jul-2017)

224.7 m

Cash (31-Mar-2017)

10.9 m
Cerus Corporation's current market capitalization is $224.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

39.7 m36.4 m34.2 m39.3 m

Revenue growth, %

(8%)(6%)15%

Cost of goods sold

22.6 m21.2 m23.5 m20.3 m

Gross profit

17.1 m15.2 m10.8 m19 m

Gross profit Margin, %

43%42%31%48%

R&D expense

31.3 b

General and administrative expense

48.8 b

Operating expense total

45.4 m59.7 m71.8 m80.4 m

EBIT

(28.3 m)(44.5 m)(61.1 m)(61.4 m)

EBIT margin, %

(71%)(122%)(178%)(156%)

Interest expense

(332 k)(599 k)(1.7 m)(2.4 m)

Pre tax profit

(43.1 m)(38.6 m)(59.5 m)(62.7 m)

Income tax expense

218 k195 k(3.7 m)175 k

Net Income

(43.3 m)(38.8 m)(55.9 m)(62.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

8.6 m10.4 m7.7 m8.8 m8 m7.6 m9.3 m

Cost of goods sold

4.8 m5.7 m4.7 m7 m5.6 m4.3 m5 m

Gross profit

3.8 m4.7 m3 m1.8 m2.5 m3.4 m4.3 m

Gross profit Margin, %

45%45%39%20%31%44%46%

R&D expense

4.7 m7.3 m5.6 m5.2 m7.7 m6.9 m8.6 m7 m9.2 m

General and administrative expense

10.1 m8.7 m11.7 m12.1 m10.9 m11.7 m12.4 m12.2 m13.6 m

Operating expense total

14.8 m16 m17.3 m17.3 m18.6 m18.7 m21 m19.2 m22.8 m

EBIT

(11 m)(11.4 m)(14.4 m)(15.5 m)(16.2 m)(15.3 m)(16.7 m)(14.3 m)(18.1 m)

EBIT margin, %

(128%)(110%)(187%)(176%)(201%)(201%)(181%)

Interest expense

(141 k)(342 k)(255 k)(301 k)(505 k)(655 k)(658 k)(586 k)(531 k)

Pre tax profit

(7.5 m)(10.8 m)(9.4 m)(18 m)(15.6 m)(16.1 m)(17.2 m)(14.8 m)(18.6 m)

Income tax expense

44 k8 k19 k(2 m)95 k812 k983 k(416 k)35 k

Net Income

(7.6 m)(10.8 m)(9.5 m)(16 m)(15.7 m)(16.9 m)(18.2 m)(14.4 m)(18.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

29.5 m22.8 m71 m22.6 m

Accounts Receivable

6.1 m5.5 m5.8 m6.9 m

Inventories

13.1 m15 m10.8 m12.5 m

Current Assets

78.2 m74.9 m130.4 m94.1 m

PP&E

2.2 m3.8 m3.5 m3 m

Goodwill

1.3 m1.3 m1.3 m1.3 m

Total Assets

83.4 m81.8 m139.5 m103.5 m

Accounts Payable

5.7 m9.9 m5.2 m8.6 m

Total Debt

3.4 m9.9 m19.8 m19.4 m

Current Liabilities

39.4 m29.2 m21.9 m26.9 m

Total Liabilities

45.7 m

Additional Paid-in Capital

545.9 m583.4 m685.2 m718.3 m

Retained Earnings

(503.2 m)(541.9 m)(597.8 m)(660.7 m)

Total Equity

42.8 m41.5 m94.8 m57.8 m

Debt to Equity Ratio

0.1 x0.2 x0.2 x0.3 x

Debt to Assets Ratio

0 x0.1 x0.1 x0.2 x

Financial Leverage

1.9 x2 x1.5 x1.8 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

28.6 m22.3 m17.9 m35.1 m50.8 m20.8 m7.7 m12.9 m10.9 m

Accounts Receivable

4.5 m7.4 m5.2 m5.4 m5.6 m4.1 m5.1 m7.4 m5.6 m

Inventories

13.4 m13.5 m16.1 m13.7 m12.8 m11.3 m12.1 m12.2 m12.9 m

Current Assets

70.3 m72.7 m136.4 m144.5 m128.4 m119.4 m112.2 m108 m75.7 m

PP&E

3.6 m3.9 m3.8 m3.8 m3.7 m3.4 m3.2 m3.2 m2.8 m

Goodwill

1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m

Total Assets

76.9 m79.4 m143.2 m151.4 m135.2 m127.9 m120.5 m116.1 m84.9 m

Accounts Payable

3.2 m4.1 m10.5 m5.8 m6.8 m6.2 m7.2 m6.9 m8.8 m

Current Liabilities

21.7 m21.2 m22.8 m22.2 m19.9 m22.8 m25.7 m22.9 m26.4 m

Common Stock

74 k77 k95 k97 k97 k101 k102 k103 k103 k

Additional Paid-in Capital

555.1 m569 m661.3 m670.3 m673.7 m694.7 m704.4 m716.2 m720.8 m

Retained Earnings

(511 m)(521.8 m)(551.4 m)(567.4 m)(583.1 m)(614.7 m)(632.8 m)(647.2 m)(679.3 m)

Total Equity

44.2 m47.3 m109.9 m110.5 m95.5 m83.5 m74.6 m72.3 m41.5 m

Financial Leverage

1.7 x1.7 x1.3 x1.4 x1.4 x1.5 x1.6 x1.6 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.3 m)(38.8 m)(55.9 m)(62.9 m)

Depreciation and Amortization

202 k202 k202 k202 m

Accounts Receivable

(1.7 m)632 k(301 k)(1.1 m)

Inventories

(1.8 m)3 m4 m(1.8 m)

Accounts Payable

(1.5 m)(973 k)(3.9 m)3.3 m

Cash From Operating Activities

(26.8 m)(39.8 m)(51.1 m)(53.5 m)

Capital Expenditures

(663 k)(2.1 m)(722 k)(563 k)

Cash From Investing Activities

(29.1 m)(3.3 m)1.4 m(19.9 m)

Long-term Borrowings

(7.6 m)(3.5 m)(113 k)(622 k)

Cash From Financing Activities

58.6 m36.5 m98 m24.6 m

Interest Paid

294 k563 k1.1 m1.4 m

Income Taxes Paid

146 k177 k153 k157 k

Free Cash Flow

(27.5 m)(41.9 m)(51.9 m)(54.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.6 m)(10.8 m)(9.5 m)(16 m)(15.7 m)(16.9 m)(18.2 m)(14.4 m)(18.6 m)

Depreciation and Amortization

51 k50 k50 k51 k50 k50 k51 k50 k50 k

Accounts Receivable

4.5 m7.4 m5.2 m5.4 m5.6 m4.1 m5.1 m7.4 m5.6 m

Inventories

13.4 m13.5 m16.1 m13.7 m12.8 m11.3 m12.1 m12.2 m12.9 m

Accounts Payable

3.2 m4.1 m10.5 m5.8 m6.8 m6.2 m7.2 m6.9 m8.8 m
Y, 2017

Financial Leverage

2 x

Cerus Corporation Operating Metrics

FY, 2016

Patents Issued

93

Cerus Corporation Market Value History

Cerus Corporation Company Life and Culture

You may also be interested in